National Cancer Institute (nci)

This study tests whether a stem cell transplant from a healthy donor can cure people with certain immune system diseases (primary immunodeficiencies). Participants, aged 4 to 69, receive donor stem cells to rebuild a healthy immune system. The goal is to see if the transplant wor…

This early-phase study tests a drug called novobiocin in people with advanced solid tumors that have specific DNA repair gene mutations (like BRCA). Novobiocin blocks a protein cancer cells need to fix their DNA, causing them to die. The goal is to find the safest dose and see if…

This early-phase trial tests whether adding the experimental drug CA-4948 to the immunotherapy pembrolizumab can help people with advanced bladder cancer that no longer responds to standard immunotherapy. About 27 adults with metastatic or inoperable urothelial cancer will receiv…

This study tests a daily pill called enasidenib in people with rare cancers of the nasal cavity or skull base that have a specific IDH2 gene mutation. The goal is to see if the drug can slow or stop tumor growth in patients whose cancer has spread or come back after other treatme…

This early-phase study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphoma that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. Up to 55 participants will receive the drugs in 21-day cycles …

This study tests whether a stem cell transplant from a healthy donor can control VEXAS syndrome, a rare and severe inflammatory disease. About 54 adults aged 18 to 75 who have not responded to standard treatments will receive donor stem cells after chemotherapy. The goal is to se…

This study tests a new two-drug combination (pidnarulex and cemiplimab) in people with advanced colorectal cancer that no longer responds to standard treatments. The goal is to find the best dose and see if the combination can slow or stop cancer growth. About 86 adults with a sp…

This study tests whether adding an immunotherapy drug (cemiplimab) to a targeted cancer drug (cabozantinib) works better than the targeted drug alone for advanced adrenocortical cancer. About 48 adults and teens whose cancer has spread or cannot be removed will take part. The goa…

This study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) to see if they can shrink or control metastatic colorectal cancer that has spread after standard treatments. About 60 adults aged 18 and older will receive the drugs f…

This study tests two non-chemotherapy drugs, PDS01ADC and M7824, in people with advanced Kaposi sarcoma (KS) that has not responded well to prior treatment. PDS01ADC helps the immune system attack tumors, while M7824 blocks cancer cells' ability to hide. The goal is to see if the…

This study is for adults aged 59 or younger with a high-risk form of acute myeloid leukemia (AML) that is harder to treat. It compares the standard two-drug chemotherapy to several newer combinations, including a liposome version of the drugs and the addition of venetoclax. The g…

This study tests whether adding chemotherapy to immunotherapy works better than immunotherapy alone for adults aged 70 and older with advanced non-small cell lung cancer. About 304 participants will receive either pembrolizumab alone or pembrolizumab plus chemotherapy. The goal i…

This study tests a drug called pacritinib for people with moderate to severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant, when other treatments have failed. cGVHD is an immune system problem that can damage organs and cause disability. The goal is to se…

This early-stage trial tests a new drug called metarrestin in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. Adults with certain cancers and children aged 12-17 with solid tumo…

This early-phase study is testing whether adding a drug called azenosertib to the existing cancer drug trastuzumab deruxtecan (T-DXd) is safe and effective for people with HER2-positive stomach, esophageal, or other solid tumors that have spread or can't be removed by surgery. Ab…

This study aims to see if adjusting the dose of the drug belinostat based on a person's genes can make treatment safer and more effective for high-grade neuroendocrine carcinomas. About 60 adults with this rare cancer will receive belinostat along with two other chemotherapy drug…

This study tests a new drug (SNDX-5613) added to standard chemotherapy for adults newly diagnosed with a type of acute myeloid leukemia (AML) that has certain gene changes (NPM1 or MLL). The goal is to find the safest dose and see if the combination works better than chemo alone.…

This study tests a new drug (CDX-1140) plus three standard cancer drugs (capecitabine, oxaliplatin, and Keytruda) in people with advanced bile duct cancer that has stopped responding to treatment. About 60 adults will receive the drugs in 21-day cycles for up to 2 years, with fol…

This study tests a drug called mirdametinib in 20 people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or not responded to prior treatments. The drug blocks a protein that helps cancer cells grow, aiming to shrink tumors or slow the dis…

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink tumors more than the immunotherapy alone in people with stage III-IV head and neck cancer. About 44 participants will receive either the combination …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before surgery can help shrink high-risk liver cancer (cholangiocarcinoma) and make surgery more effective. About 27 adults with resectable cancer will receive the combination, then undergo…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific change in the β-catenin gene. The goal is to find the best dose and see if the combination works better than cabozantinib alone. About 92 adults with liver…

This early-phase trial tests whether adding pidnarulex to the targeted therapy trastuzumab deruxtecan is safe and effective for people with advanced HER2-positive breast cancer or other solid tumors that have spread or can't be removed. About 36 adults whose cancer has stopped re…

This study tests a new drug that delivers radiation directly to cancer cells in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paraganglioma that have already been treated with radiation therapy. The drug homes in on a protein found on these tumor…

This study tests whether adding the experimental drug PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread. About 86 men with either castration-sensitive or castration-resistant disease will receive treatment in 21-day cycles. The goal i…

This study tests a drug called TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take the drug daily for up to 2 years and are clos…

This study is testing a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with rare genitourinary cancers that have spread. The goal is to see if this mix can shrink tumors better than any single drug alone. About 314 adults with these rare cancers wi…

This early-stage trial tests a combination of four drugs (methotrexate, rituximab, lenalidomide, and nivolumab) in people with primary CNS lymphoma, a rare cancer of the brain or spinal cord. The goal is to find the safest dose of lenalidomide when added to the other drugs, and t…

This study tests whether adding a second immunotherapy drug (relatlimab) to the usual maintenance treatment (nivolumab) can help keep Epstein-Barr virus-related nasopharyngeal cancer from returning or spreading longer. About 156 adults whose cancer has come back or spread will re…

This study is for people living with HIV who also have a blood cancer that needs a bone marrow transplant. Researchers are testing a new combination of drugs to prevent a serious side effect called graft-versus-host disease (GVHD) after the transplant. The goal is to make the tra…

This early-phase study tests two drugs—DS-8201a and olaparib—together in people with advanced HER2-positive cancers that have spread or can't be removed. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors. About 55 adults with certain so…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before surgery helps shrink tumors in people with high-grade upper tract urothelial cancer. About 249 adults will be randomly assigned to receive either the drug combo or chemo alone before…

This early-phase study tests a new drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has returned or stopped responding to treatment. The main goals are to find the best dose and check for side effects. TAK-243 works by blocking enzymes that c…

This study tests a drug called PT-112 in people with thymoma or thymic carcinoma that has come back or worsened after standard treatment. The drug aims to shrink tumors by killing cancer cells and boosting the immune system. About 53 adults will receive PT-112 infusions every few…

This study tests whether a targeted drug called selumetinib works as well as standard chemotherapy (carboplatin and vincristine) for children and young adults with a slow-growing brain tumor called low-grade glioma. Participants must be 2 to 21 years old and have a tumor without …

This early-phase trial tests a new oral drug, Aza-TdC, in adults with advanced solid tumors that have not responded to standard treatments. The drug aims to 'turn back on' genes that may slow tumor growth. The main goals are to check safety and find the best dose.

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can shrink tumors in people with certain cancers that have spread to the liver. About 70 adults with colorectal, bile duct, or adrenal cancer will receive t…

This study tests a drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood disorders. The drug is taken as a capsule twice daily and aims to control the disease by blocking certain proteins that help cancer grow. Researchers will f…

This early-phase trial tests a new drug that delivers radiation directly to cancer cells with a specific protein (SSTR) on their surface. It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be removed by surgery. The go…

This early-phase trial tests a new treatment for children and young adults (ages 3–39) with rhabdomyosarcoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and attack the cancer. Th…

This study compares two treatments for a type of bladder cancer that hasn't spread into the muscle. One group gets an immunotherapy drug (pembrolizumab) plus radiation, while the other gets standard chemotherapy plus radiation. The goal is to see which approach better prevents th…

This study tests a drug called pacritinib for people with HIV who have two rare, serious conditions caused by a virus (KSHV): multicentric Castleman disease (MCD) and inflammatory cytokine syndrome (KICS). These conditions cause severe inflammation that can be life-threatening. T…

This early-phase trial tests a combination of two drugs—teclistamab and iberdomide—in people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to find the safest and most effective dose of iberdomide when used with teclistamab. About …

This study tests a pill called osimertinib in people with advanced lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 46 participants will take the drug daily, and researcher…

This study compares the drug neratinib alone versus neratinib plus palbociclib in people with HER2-positive gynecologic or other solid tumors (excluding breast cancer). Both drugs block signals that make cancer cells grow. The goal is to see if the combination shrinks or stabiliz…

This study is for younger adults with a certain type of acute myeloid leukemia (AML) that has an intermediate risk. It tests whether adding the drug venetoclax to standard chemotherapy can clear more cancer cells from the bone marrow than standard treatment alone. About 153 peopl…

This study compares starting treatment right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants receive two drugs: venetoclax (which blocks a protein that helps cancer cells …

This study tests whether a newer drug, mosunetuzumab, works better than the standard drug rituximab for people with a rare type of Hodgkin lymphoma called NLPHL. Both drugs help the immune system attack cancer cells. About 70 adults who need treatment for their lymphoma will be r…

This study tests a drug called pidnarulex (CX-5461) in people with aggressive B-cell lymphomas that have MYC gene changes. The goal is to find a safe dose and see if it shrinks tumors. About 50 adults who have already tried other treatments will take part. This is an early-phase …

This study tests imatinib, a pill taken daily, in adults with a faulty RUNX1 gene that causes easy bleeding and a higher risk of blood cancers. The goal is to find the best dose and see if it improves platelet function and reduces inflammation. Healthy family members are also nee…

This study tests whether taking two oral drugs (encorafenib and binimetinib) together works better than the current drug for hairy cell leukemia that has returned or not responded to treatment. About 45 adults with a specific gene mutation (BRAF V600) will take the pills daily in…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people whose B-cell lymphoma has returned or not improved after prior treatment. The goal is to see if this drug mix is safe and can control the cance…

This early-phase trial tests the safety and best dose of two drugs—ZEN003694 and abemaciclib—given together to people with advanced breast cancer, NUT carcinoma, or other solid tumors that have spread or can't be removed by surgery. The goal is to see if the combination can shrin…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and advanced cancer that has spread or cannot be removed. It tests a drug called nivolumab, which helps the immune system fight cancer, given alone or with other…

This study tests whether combining two drugs—pembrolizumab (an immunotherapy) and sacituzumab govitecan (a targeted chemotherapy)—works better than standard chemotherapy for people with advanced bladder cancer that no longer responds to immunotherapy. About 320 adults with locall…

This study tests whether a combination of two immune-boosting drugs (pembrolizumab and N-803), with or without special cancer-killing cells (PD-L1 t-haNK cells), can shrink tumors in people with head and neck cancer before they have surgery. About 40 adults with advanced but remo…

This early-phase study tests a new drug called rhIL-15 alongside three standard chemotherapy drugs for children and young adults (ages 3 to 35) with neuroblastoma that has returned or not responded to prior treatment. The goal is to find a safe dose and see if the combination can…

This study is for people with a high-risk type of myelodysplastic syndrome (MDS) that has a specific gene change called IDH2. It compares the usual treatment (cedazuridine-decitabine) to the same treatment plus an added drug (enasidenib). The goal is to see if the combination lea…

This study tests two approved cancer drugs—sacituzumab govitecan and atezolizumab—alone or together in people with rare genitourinary tumors, such as certain bladder, kidney, and penile cancers. About 60 adults will receive the drugs through an IV, and researchers will track how …

This early-phase trial tests a new way to use radiation before surgery for people whose adrenal cancer has come back. The goal is to find the safest radiation dose and see if it helps control the disease. About 32 adults with resectable tumors will receive daily radiation for 2-3…

This study tests a new treatment for children and young adults with a specific type of leukemia (Ph+ or Ph-like B-ALL). The treatment combines standard chemotherapy with targeted drugs (dasatinib or imatinib) and an immunotherapy drug (blinatumomab) that helps the immune system a…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with a rare, aggressive cancer that starts outside the lungs. About 189 adults with advanced or metastatic disease will receive either chemo alone or chemo plus atezolizumab.…

This study tests whether adding chemotherapy or a chemo-immunotherapy combination before standard salvage surgery helps people with a specific type of head and neck cancer that has come back or persisted. About 180 adults with PD-L1 positive cancer will be randomly assigned to on…

This early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe for people with advanced head and neck cancer. Ipatasertib may help stop cancer cells from growing. The study involves about 46 adults and aims to find the…

This study tests a daily pill called venetoclax in 20 adults whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that helps cancer cells survive. Researchers will measure how many patients achieve remission and how long the benefits last.

This study tests whether giving an extra round of chemotherapy and immunotherapy (pembrolizumab) before the usual chemoradiation can help people with high-risk, locally advanced cervical cancer live longer without the disease getting worse. About 336 participants will be randomly…

This study tests whether adding a drug called bevacizumab to standard chemotherapy plus immunotherapy works better for advanced or recurrent endometrial cancer with specific genetic changes (pMMR and TP53 mutated). About 255 participants will receive one of three treatment combin…

This study tests whether giving the immunotherapy drug pembrolizumab along with radiation therapy after chemotherapy can help people with muscle invasive bladder cancer keep their bladder instead of having it surgically removed. About 111 participants will receive this combinatio…

This study tests a drug called erdafitinib in people with a specific type of brain tumor (glioma) that has come back or is growing. The drug targets a faulty protein that helps the tumor grow. About 30 adults will take the pill to see if it can shrink or slow the tumor.

This study tests whether adding abemaciclib to the chemotherapy drug gemcitabine is safe and works better than the usual treatment for advanced soft tissue sarcomas. About 74 adults with certain sarcoma types that have spread will receive the new combination. The goal is to slow …

This study tests whether combining two drugs—pembrolizumab (an immunotherapy) and aldesleukin (a protein that boosts immune cells)—can shrink tumors in people with advanced melanoma or kidney cancer that has not responded to standard treatments. About 78 adults will receive the d…

This study tests whether a newer drug, mosunetuzumab, works better than the standard drug rituximab for people with a slow-growing type of lymphoma that has not spread much. About 600 adults will be randomly assigned to receive one of the two treatments. The main goal is to see w…

This study tests a new drug, tovorafenib, combined with rituximab for people with classical hairy cell leukemia that has returned or not responded to treatment. It also compares this combination to the standard treatment (cladribine plus rituximab) for newly diagnosed patients. T…

This study is for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy plus immunotherapy. It compares the usual maintenance immunotherapy (atezolizumab) alone versus adding radiation therapy to see if the combination delays cancer…

This study tests two drugs—cabozantinib and nivolumab—in people with advanced melanoma or head and neck cancer that has stopped responding to immunotherapy. The goal is to see if the combination can shrink or stabilize tumors, and whether certain biological markers in the tumor c…

This study is for people with a type of sinus cancer called sinonasal squamous cell carcinoma. It compares standard chemotherapy alone to chemotherapy plus an immunotherapy drug (cemiplimab) given before surgery. The goal is to see if adding immunotherapy helps shrink tumors more…

This study tests two drugs—palbociclib (a daily pill) and sasanlimab (a monthly shot)—in 100 adults with advanced kidney cancer (clear cell or papillary type). The goal is to see if the combination can shrink tumors or stop them from growing. Participants receive treatment in 28-…

This early-phase trial tests whether a patient's own white blood cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain T-cell lymphomas that have not responded to standard therapy. About 60 adults with relapsed or refract…

This study tests a personalized gene therapy for people with metastatic cancers (including lung, breast, ovarian, and others) that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to better attack the cance…

This study tests whether adding nivolumab to blinatumomab helps children and young adults (ages 1 to 30) whose B-cell acute lymphoblastic leukemia has returned after initial treatment. Participants receive either blinatumomab alone or with nivolumab. The goal is to see if the com…

This study tests whether combining two drugs, Lutathera and Olaparib, can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive Lutathera by IV every 8 weeks and take Olaparib pills twice daily. The goal is to fi…

This study tests a treatment called CAR T-cell therapy for people with advanced B-cell leukemias or lymphomas that haven't responded to standard drugs. Participants' own immune cells are collected, modified to recognize and attack cancer cells, and then returned to the body. The …

This study tests whether giving a lower dose of the cancer drug atezolizumab less often can still control tumors while causing fewer side effects. About 30 adults with advanced cancers like lung, liver, or melanoma will receive the drug, with doses adjusted based on blood levels.…

This study compares two treatments for head and neck cancer that has returned or spread and no longer responds to standard platinum chemotherapy. One group gets the immunotherapy drug pembrolizumab alone; the other gets pembrolizumab plus cetuximab, which targets a protein on can…

This early-phase trial tests a combination of two targeted drugs, abemaciclib and olaparib, in people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The main goal is to find the safest dose and understand side effects. About 42 participants will b…

This study tests a lab-made protein called CYT107 in 55 adults with HIV-related Kaposi sarcoma who have low T-cell counts. The goal is to see if weekly injections for up to 4 weeks can shrink tumors by boosting the immune system. Participants who improve may receive another round…

This study tests whether two drugs, ZEN-3694 and talazoparib, can shrink tumors in people with advanced solid cancers that have spread or cannot be removed. About 88 adults will take part. The study also looks at how a person's genes might affect whether the treatment works. The …

This study tests a new drug, ZEN003694, combined with standard chemotherapy for people with a rare and aggressive cancer called NUT carcinoma. The goal is to find the safest dose and see if the combination can shrink tumors. About 36 adults with advanced or metastatic NUT carcino…

This study tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system better fight prostate cancer. About 65 adults with high- or intermediate-risk prostate cancer that hasn't spread will take part. The goal is t…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors, including mesothelioma, that have not responded to standard therapy. The treatment involves collecting a patient's own immune cells, modifying them in a lab to recognize and att…

This study tests whether adding the drug dinutuximab to standard chemotherapy and other treatments helps children with high-risk neuroblastoma live longer without the cancer coming back. About 478 children and young adults up to age 30 with newly diagnosed high-risk neuroblastoma…

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants with newly diagnosed ALL will take part. The goal is to …

This study tests whether adding two new drugs (M3814 and avelumab) to standard radium-223 therapy can better control advanced prostate cancer that has spread to bones. About 90 men with castration-resistant prostate cancer will receive either radium-223 alone or with one or both …

This study is for women whose ovarian or endometrial cancer has returned or not gone away and has a specific change in the RAS gene. It compares taking two drugs (selumetinib and olaparib) versus selumetinib alone. The goal is to see if the combination can shrink tumors or keep t…

This study is testing whether a blood or bone marrow transplant from a healthy donor can help people aged 4 to 75 with serious immune system disorders. Participants receive chemotherapy before the transplant and must stay near the clinic for months after. The goal is to control t…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (doxorubicin) helps people with certain advanced sarcomas live longer without their cancer growing. The trial includes about 365 adults whose sarcoma has spread or cannot be removed by …

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma that has spread. About 170 adults aged 18 to 72 with skin melanoma that hasn't responded to prior t…

This study tests whether adding the drug cabozantinib to the immunotherapy nivolumab can prevent mucosal melanoma from returning after surgery. Mucosal melanoma is a rare and aggressive cancer that forms in moist body linings. About 100 adults who have had their melanoma surgical…

This early-stage study tests a new oral drug called pidnarulex in 40 adults with advanced solid tumors that have spread and stopped responding to standard treatments. The drug works by blocking a key enzyme cancer cells need to divide and repair their DNA. The main goal is to see…

This early-phase study tests a combination of two experimental drugs (M1774 and ZEN-3694) in people whose ovarian or endometrial cancer has returned after previous treatment. The goal is to find the safest dose and see how well the drugs work together to stop cancer growth. About…

This study tests whether giving the immunotherapy drug durvalumab after surgery can help prevent early-stage non-small cell lung cancer from returning. About 306 people who have had their lung cancer completely removed will either receive durvalumab or be closely watched without …

This study tests whether retreating with a radioactive drug (177Lu-DOTATATE) can better control advanced gastroenteropancreatic neuroendocrine tumors (GEPNETs) compared to switching to standard drugs like everolimus, sunitinib, or cabozantinib. About 100 adults whose tumors have …

This study looks at whether a blood test that detects cancer DNA can help decide who needs extra immunotherapy after bladder cancer surgery. About 992 people who had their bladder, kidney, ureter, or urethra removed will be enrolled. The goal is to see if giving the immunotherapy…

This early-phase study tests a personalized treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that have a specific marker called GPC3. The study includes adults with advanced liver cancer or other solid tumors that expr…

This early-phase study tests whether combining a targeted drug (olaparib), an immunotherapy (durvalumab), and radiation is safe for people with locally advanced pancreatic cancer that cannot be surgically removed. About 18 participants will receive the combination after initial c…

This early-phase trial tests whether adding an experimental drug (ZEN003694) to standard chemotherapy and immunotherapy is safe and can shrink tumors in people with advanced triple-negative breast cancer. About 57 participants will receive the combination. The goal is to find the…

This early-phase study tests whether adding inhaled antibiotics (aztreonam and vancomycin) to the standard cancer drug pembrolizumab can help control advanced non-small cell lung cancer. About 23 adults whose cancer has returned or spread will receive the combination over six 21-…

This study tests a new way to treat early-stage prostate cancer using MRI-guided ultrasound. The procedure, called TULSA, uses heat from a small device placed in the urethra to destroy cancer areas in the prostate. About 21 adults with localized prostate cancer will take part. Th…

This early-phase study tests a combination of two drugs—pomalidomide (a pill) and nivolumab (an IV infusion)—in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors or slow disease. Part…

This study looks at whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after lung cancer surgery can help people live longer without the cancer coming back. About 1,210 adults with stage II to IIIB non-small cell lung cancer that was removed by surgery w…

This study tests a drug called M3814 (Peposertib) together with a special type of radiation for people with locally advanced pancreatic cancer. The goal is to find the best dose and see if the combination is safe and works better than radiation alone. About 92 adults who have alr…

This early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and nerve sheath tumors. The drug is given through a vein and aims to shrink or control tumors. The study will check safety, find the best dose, and see…

This early-phase study tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have certain aggressive lymphomas. About 25 adults with high-risk features will receive up to 6 cycles of treatment…

This study tests whether a shorter course of radiation can safely treat glioblastoma that has returned after initial treatment. About 28 adults with recurrent grade 4 brain tumors will receive focused radiation 4 times a week for 1 to 3 weeks. The goal is to find the safest sched…

This study tests whether adding bevacizumab to the standard drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 300 adults with stage IIIB or IV disease will receive either the combination or osimertin…

This study tests a drug called binimetinib for people with hairy cell leukemia that lacks the BRAF gene mutation, making standard treatments ineffective. About 40 adults whose cancer returned or didn't respond to prior therapy will take the pill twice daily. The goal is to see if…

This early-stage study tests the safety and best dose of TAK-243, a drug that targets a protein cancer cells need to grow. About 95 adults with advanced solid tumors or lymphoma who have tried other treatments will receive TAK-243. The goal is to find side effects and the right d…

This study tests whether adding a personalized vaccine (made from unique tumor proteins) to a standard chemo-immunotherapy combination can better control metastatic triple-negative breast cancer. About 70 participants will receive either the vaccine plus immunotherapy or immunoth…

This study tests a drug called abemaciclib for people with NF1 who have nerve tumors (atypical neurofibromas) that can't be removed by surgery. The goal is to find a safe dose and see if the drug can shrink or control the tumors. Participants take the drug twice daily for up to 2…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) helps people with advanced stomach or esophageal cancer live longer without their disease getting worse. About 224 adults whose cancer has a specific marker (PD-…

This early-phase study tests a personalized treatment for people with certain blood cancers, including acute myeloid leukemia and myelodysplastic syndrome. Researchers take a patient's own immune cells, modify them in the lab to recognize unique markers on their cancer cells, and…

This early-phase study tests whether a customized immune cell therapy (anti-CD22 CAR T cells) is safe for people with hairy cell leukemia (classic or variant) that has returned or not responded to standard treatments. Up to 27 adults will receive the therapy after mild chemothera…

This study is for people with a type of recurrent endometrial cancer that has a specific DNA repair problem (dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against nivolumab alone to see which shrinks tumors better. About 81 participants wi…

This study tests a drug called selinexor combined with standard radiation for children and young adults with newly diagnosed aggressive brain tumors (DIPG or H3 K27M-mutant high-grade glioma). The goal is to find the safest dose and see if the combination can shrink tumors. About…

This study tests whether taking iberdomide pills after CAR-T therapy can keep multiple myeloma under control longer than just watching and waiting. About 78 people who have already received the CAR-T treatment idecabtagene vicleucel will be randomly assigned to either take iberdo…

This early-stage trial tests whether adding an experimental drug (ZEN003694) to a standard chemotherapy (capecitabine) is safe and tolerable for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 adults whose cancer has worsened after stan…

This early-stage trial tests whether combining two targeted drugs—sunitinib malate and lutetium Lu 177 dotatate (Lutathera)—is safe and effective for people with advanced pancreatic neuroendocrine tumors. The study involves 24 participants and aims to find the best dose while mon…

This early-phase trial tests whether adding the experimental drug CA-4948 to standard chemotherapy (FOLFOX) and a blood-vessel blocker (bevacizumab) is safe and tolerable for people with metastatic colorectal cancer that cannot be removed by surgery. About 24 adults will take par…

This study tests whether adding the drug cabozantinib to standard chemotherapy works better than chemo alone for people under 40 with newly diagnosed osteosarcoma, a type of bone cancer. Cabozantinib blocks signals that help tumors grow and form blood vessels. The trial will chec…

This study tests a drug called durvalumab (an immunotherapy) combined with chemotherapy in people with advanced solid tumors that have spread or can't be removed. The goal is to see if the combo is safe and helps the immune system fight the cancer better. About 115 adults whose c…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can better prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) in people with blood cancers like leukemia or lymphoma. About 2…

This study tests a drug called daratumumab in people with three rare and aggressive blood cancers: primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease. These cancers often do not respond to standard treatments. The drug is given as a shot under t…

This study compares the immunotherapy drug pembrolizumab (Keytruda) alone against the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 with high-risk features like posi…

This study tests two drugs, enfortumab vedotin and pembrolizumab, in people with rare bladder or testicular cancers that have spread. About 68 adults will receive the drugs through an IV, either together or alone, for up to 5 years. The goal is to see if the treatment can shrink …

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This early-phase study tests whether combining two drugs—nivolumab (an immunotherapy that helps the immune system attack cancer) and ASTX727 (a two-drug pill that makes cancer cells easier to kill)—is safe and effective for people with B-cell lymphoma that has returned or stopped…

This study tests a drug called TPST-1495 in 38 people with familial adenomatous polyposis (FAP), an inherited condition that causes many polyps in the colon and small bowel and raises colon cancer risk. The drug works by blocking certain signals that help polyps grow. The main go…

This study tests whether a new drug combination (amivantamab plus hyaluronidase) works as well as or better than the standard drug cetuximab for treating skin squamous cell carcinoma that has returned or spread. The trial enrolls 86 immunocompromised adults, including organ trans…

This study tests whether a special imaging agent called 18F-DCFPyL, used during PET scans, can better detect how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive PET/CT scans before and after tre…

This study tests a low-dose tamoxifen plan to lower breast density, a key risk factor for breast cancer, in 200 premenopausal women at higher-than-average risk. Participants start on a low dose, and if their breast density doesn't drop enough, the dose is increased. The goal is t…

This study tests whether obeticholic acid can prevent cancer in people with Barrett's esophagus, a condition that raises the risk of esophageal cancer. The drug works by reducing damage from bile acids that flow back into the esophagus. About 30 adults with Barrett's esophagus wi…

This study looks at whether adding high-dose omega-3 fatty acids to low-dose tamoxifen can better reduce breast cancer risk in overweight postmenopausal women who are already at higher risk. Tamoxifen blocks estrogen in breast tissue, while omega-3s may help with fat-related canc…

This early-stage trial tests the safety of a drug called ONC201 (dordaviprone) in 36 people with a high risk of colorectal cancer due to familial adenomatous polyposis (FAP) or a history of many polyps. The drug aims to kill precancerous cells without harming normal tissue. If sa…

This study tests a device that sends mild electrical pulses through the skin to strengthen pelvic muscles and reduce urine leakage in men who have had prostate cancer treatment. About 41 men with moderate leakage for at least 6 months will use the device at home for 20 minutes a …

This study works to improve questionnaires that measure pain, daily activities, and physical function for people with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas (pNFs). Participants aged 5 and older will give feedback on existing surveys through group discuss…

This study is developing a new questionnaire to help children and teens (ages 5-17) with chronic graft-versus-host disease (cGVHD) describe their symptoms and how bothersome they are. cGVHD is a common side effect after a stem cell transplant, and current symptom scales are desig…

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that may explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treatme…

This study is testing whether a special PET/CT scan using a radioactive tracer called 18F-DCFPyL can find prostate cancer that has come back after initial treatment. About 350 men whose cancer has returned will be scanned and followed for up to 5 years. The goal is to see how wel…

This study looks at whether having guided conversations about care priorities helps young adults (ages 18-39) who are about to get a stem cell transplant, along with their caregivers. Participants will fill out questionnaires and have three talks with a study team member over sev…

This study aims to learn how genes and the environment work together to cause rare tumors and cancer in individuals and families. Up to 500 people of any age who have unusual tumors, a family history of cancer, or certain exposures can join. Participants answer questions, share m…

This study screens adults with certain cancers (like melanoma, lung, or bladder cancer) to see if they qualify for experimental treatments that use their own white blood cells to fight the tumor. Participants undergo tests and evaluations, but no treatment is given in this study.…

This study collects blood or cheek swab samples from 1,100 people with cancer who are already in treatment at the National Cancer Institute. Researchers will analyze the DNA to find genetic differences that might make certain treatments more toxic or less effective. The goal is t…

This study tests whether frequent blood and bone marrow tests can help doctors know if a child's leukemia will come back after CAR T-cell therapy. About 60 children and young adults (ages 1-25) who have no detectable cancer after CAR T will be followed for 2 years. The goal is to…

This study follows people with a rare inherited condition called DICER1 syndrome, which raises the risk of certain lung, kidney, and other tumors. Researchers collect medical history, genetic samples, and imaging from affected individuals and their close relatives to learn how th…

This study is looking at why some prostate cancers return after radiation treatment. Researchers will use detailed MRI scans and biopsies to check the prostate before and after radiation in 300 men. The goal is to better understand treatment failure and improve future care.

This study is testing two questionnaires to see if they can measure how visible tumors affect appearance concerns in people with Neurofibromatosis Type 1 (NF1). About 110 participants, including children, adults, and caregivers, will join focus groups or interviews to share their…

This study follows 150 adults with Kaposi sarcoma (KS) to understand how the disease develops, changes, and may come back over time. Researchers will track participants for up to 10 years using exams, scans, and biopsies. The goal is to learn more about KS, not to test a new trea…

This study follows people who have had or will have a stem cell transplant, plus their donors, for many years. Researchers want to learn about long-term side effects and how the transplanted cells change over time. Participants will have yearly check-ups, blood tests, and answer …

This study follows people with von Hippel-Lindau (VHL) disease who have pancreatic tumors or cysts. The goal is to learn how these growths change over time and to test if a special type of PET scan can find them better. Participants will have regular check-ups and imaging for lif…

This study follows people with Fanconi anemia, a rare inherited condition that raises the risk of certain cancers, especially squamous cell carcinoma. Researchers will screen 200 participants aged 12 and older every year for up to 10 years using exams, blood tests, and imaging to…

This study gathers medical records and scans from 10,000 men with prostate cancer or at high risk. Researchers aim to find patterns in imaging that could lead to better diagnosis and treatment. No new drugs or procedures are tested; it is purely an observational data collection.

This study follows up with people who previously received a type of gene therapy (using poxviral vectors) for cancers like prostate, liver, breast, colon, or lung cancer. The goal is to track their health for 15 years through yearly check-ups or phone calls to watch for any long-…

This study collects extra blood, urine, and tumor samples from children and adults with childhood cancers to create a large tissue bank. Researchers will use these samples to study the genes and proteins of these cancers. The goal is to better understand these diseases, not to te…

This study is following 1,100 adults with common and rare urinary tract cancers (like bladder, kidney, or testicular cancer) to understand how these cancers behave over time. Researchers will collect medical records, blood and urine samples, and tumor tissue to track disease prog…

This study follows children and adults with olfactory neuroblastoma, a rare cancer of the nasal cavity, to understand how the disease progresses and responds to treatments. Participants provide blood samples, complete surveys, and may have smell tests, scans, or biopsies. The goa…

This study looks at whether advanced MRI scans can better track prostate cancer in men who choose active surveillance (no immediate treatment). About 500 men with low- or intermediate-risk prostate cancer will get regular MRIs alongside standard tests like PSA blood tests and bio…

This study aims to learn more about KSHV inflammatory cytokine syndrome (KICS), a newly recognized disease caused by a virus that can also lead to certain cancers. Researchers will collect medical history, blood, urine, and tissue samples from 140 adults with KICS to describe its…

This study follows 2,000 men with prostate cancer who have specific gene changes. Researchers want to learn how these genes affect the cancer's growth and response to treatments. Participants are contacted every 6 months and provide medical records, and some give blood or urine s…

This study follows 500 men aged 30–75 who have specific genetic changes that increase their risk for prostate cancer but have not been diagnosed with it. Researchers will track their health over time using yearly checkups, blood tests, and MRI scans every two years to understand …

This study is testing new blood tests that look for signs of many different cancers at the same time. Researchers want to see if these tests can find cancer early, when treatment works best. About 24,000 adults aged 45 to 75 who do not have cancer will be split into three groups:…

This study aims to create a large collection of tissue samples from people with head and neck disorders, such as hearing loss, mouth diseases, or throat cancer. Researchers will use leftover tissue from medical procedures and collect additional samples like blood, saliva, or chee…

This study follows 500 people of all ages who have or may have a RASopathy—a group of genetic conditions that can affect development and raise cancer risk. Researchers will collect medical history, blood, urine, and saliva samples, and may perform imaging and specialist exams. Th…

This study follows 300 people aged 2 and older with chordoma, a rare bone cancer of the skull or spine. Researchers will track how the disease changes over time using scans, exams, and surveys. The goal is to learn more about chordoma so future treatments and support can be impro…

This study looks at anxiety related to cancer screenings in adults with Fanconi anemia, a rare inherited condition that raises cancer risk. Researchers will observe 20 participants during their regular screening visits, noting body language, worries, and the clinic environment. T…

This study collects blood, urine, saliva, and tumor tissue from people with or at risk for urothelial cancer, as well as from healthy volunteers. The goal is to analyze DNA and other molecular changes to learn what causes this cancer and how it responds to treatment. Participants…

This study is for adults getting a stem cell transplant for blood cancers like leukemia or lymphoma. It collects DNA from blood, skin, hair, and cheek cells before and after transplant to see how the donor's genes change drug processing. The goal is to find the best way to test a…

This study collects blood, urine, saliva, and tumor tissue from men with prostate cancer to learn how genetic changes cause the disease. Researchers hope this knowledge will lead to new treatments. Participants must be 18 or older and willing to provide samples during their regul…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers grow and why some respond differently to treatment. Participants may also have imaging scans and a…

This study collects blood, tissue, urine, saliva, and stool samples from adults with cancer (and healthy volunteers) to learn how certain immune cells change before and after chemotherapy. Researchers will also analyze genetics and link results to patient outcomes. No treatment i…

This study follows children and adults with medullary thyroid cancer (MTC) and the genetic condition MEN2 to learn how the disease grows and changes over time. Participants do not receive treatment through the study but get regular checkups, blood tests, and scans every 6 to 12 m…

This study aims to understand why some people and families are more likely to develop melanoma, a serious skin cancer. Researchers will collect medical history, blood or cheek cell samples, and skin samples from up to 3,000 participants with a personal or family history of melano…

This study collects blood stem cells from people with DOCK8 deficiency, LAD-1, or GATA2 deficiency to test gene-correction methods in the lab. Participants receive daily injections of a drug to move stem cells into the bloodstream, then donate cells through a procedure called aph…

This study follows up to 700 people who have already received radiation therapy for cancer. Researchers want to learn about the long-term side effects of radiation and how the disease progresses over time. Participants do not receive any new treatments—only standard follow-up car…

This study collects tumor and normal tissue samples from people already scheduled for surgery or biopsy at the NIH Clinical Center. The goal is to provide researchers with samples to discover new molecular targets for cancer therapies. Up to 1800 adults and children (age 2+) with…

This study looks at whether a device that measures eye pupil changes can help assess pain and other unusual sensations in people with neurofibromatosis type 1 (NF1). Researchers will test the device on 70 participants aged 1 year and older with NF1. The goal is to find a better, …

This study collects tissue and fluid samples (like blood, urine, and tumor tissue) from up to 5,000 adult and pediatric cancer patients at the NIH Clinical Center. The samples are used for research to better understand cancer and develop new tests and treatments. Participants don…

This study follows people with a gene change (DDX41) that raises the risk of blood cancers like MDS and AML, along with their relatives. Researchers will collect health information, blood, and other samples over 10 years to learn how these inherited risks lead to cancer. No treat…

This study follows 195 adults with KSHV-associated multicentric Castleman disease (MCD) to understand how the disease behaves over time. Researchers will track symptoms, treatment responses, and survival. Participants receive standard care and regular check-ups for up to 3 years.…

This study enrolls people with cancer who are already participating in other studies at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a participant's past, current, and future studies. The goal is to better under…

This study follows up to 1,100 people with myelodysplastic syndromes (MDS) and healthy donors for up to 20 years. Researchers collect blood, bone marrow, and other samples to learn how the disease progresses and to find better treatments. No experimental therapy is given; the goa…

This study collects white blood cells from healthy volunteers to help researchers develop new cancer treatments that use the body's own immune system. Participants must be 18 or older and in good health. The donation process, called apheresis, takes 4-6 hours and can be repeated …

This study is collecting blood and urine samples from 200 adults with glioblastoma (a serious brain tumor) who are receiving radiation therapy. Researchers want to see if levels of two proteins, VEGF and MMP, can help predict whether the tumor will come back within one year. The …

This study tests a redesigned surgical tool for removing bladder tumors. The goal is to see if the new device helps doctors get better tissue samples, which may show whether all cancer has been removed. About 25 adults who need their bladder removed will take part. The study only…

This study screens up to 2,000 adults with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. Researchers test blood and bone marrow for specific markers to see if participants can join a treatment trial that targets their cancer type. The goal is to make the mat…

This study looks at what happens to HIV in the body when people stop their daily HIV medication for a short time. Researchers will use PET/CT scans and lymph node biopsies to compare virus levels in the blood and lymph nodes. The goal is to understand where HIV hides, not to find…

This study is testing a new technology called SmartMatch that checks how a person's brain tumor tissue reacts to different drugs. The goal is to see if the test can give results within 21 days after surgery. About 80 people aged 15 and older with recurrent brain tumors who are al…

This study aims to collect tumor, normal tissue, and blood samples from up to 1,310 people with cancers of the lung, esophagus, or chest lining. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify patients who may be eligible f…

This study aims to collect tumor and healthy tissue samples from up to 2,415 people scheduled for surgery or biopsy of endocrine tumors (thyroid, parathyroid, adrenal, pancreas, or neuroendocrine). Researchers will analyze the samples to find genetic and molecular differences bet…

This study collects samples like blood, bone marrow, skin, saliva, and stool from 1,000 healthy adults aged 18 and older. The samples are used as a comparison to better understand myelodysplastic syndromes (MDS), a group of bone marrow disorders that can lead to blood cancer. Par…

This study collects tumor tissue, blood, and other samples from 2,000 adults with certain lung and thymic cancers. Researchers will also track participants' health over time. The goal is to better understand these cancers and support the development of new treatments.

This study aims to collect blood, tissue, and other samples from 200 adults with untreated follicular lymphoma. Researchers will track participants for up to 5 years to see how the cancer evolves and responds to therapy. The goal is to better understand the disease to design futu…

This study aims to understand how neuroendocrine neoplasms (rare cancers of hormone-producing cells) grow and change over time. Researchers will follow 300 adults with these tumors, collecting blood, urine, and tissue samples, and tracking their health yearly. No experimental tre…